We recently evaluated the cost-effectiveness of population-based panel testing for OC and BC gene mutations (BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2) by comparing this strategy to the usual clinical-criteria/FH based testing for both UK and US health systems [33]. Here, BRCA1 is linked to breast cancer.